> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Review ChemoCentryx Vasculitis NDA
- URL: https://www.fdaweb.com/panel-to-review-chemocentryx-vasculitis-nda/
- Published: 2021-03-26T12:00:00.000Z
- Updated: 2026-09-14T16:52:30.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5148978

*Federal Register* notice: FDA has announced a 5/6 Arthritis Advisory Committee meeting. Panel members are scheduled to discuss a ChemoCentryx NDA for avacopan oral capsules, indicated for treating anti-neutrophil cytoplasmic antibody-associated vasculitis. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-03-26/pdf/2021-06265.pdf?ref=fdaweb.com).